• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (88)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatologic Disorders  • Randomized Controlled Trial  • Psoriasis  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Results of a Randomized, Placebo-Controlled, Phase 2 Trial

Alexa B. Kimball, MD, MPH; Kenneth B. Gordon, MD; Richard G. Langley, MD; Alan Menter, MD; Elliot K. Chartash, MD; Joaquin Valdes, MD; for the ABT-874 Psoriasis Study Investigators

Arch Dermatol. 2008;144(2):200-207.

Objective  To investigate the efficacy and safety of ABT-874, an interleukin 12/23 monoclonal antibody, in psoriasis.

Design  Phase 2, 12-week, multicenter, randomized, double-blind, placebo-controlled trial.

Setting  Outpatient dermatology clinics.

Patients  One hundred eighty patients with clinically stable moderate to severe chronic plaque psoriasis.

Interventions  Patients were randomized in groups of 30 to receive 1 of 6 treatments with ABT-874 provided as a subcutaneous injection: one 200-mg dose at week 0; 100 mg every other week for 12 weeks; 200 mg weekly for 4 weeks; 200 mg every other week for 12 weeks; 200 mg weekly for 12 weeks; or placebo.

Main Outcome Measure  At least a 75% reduction in the Psoriasis Area and Severity Index.

Results  The percentage of patients achieving a 75% reduction in the Psoriasis Area and Severity Index at week 12 was statistically significantly greater in all of the ABT-874 treatment groups than in the placebo group (200 mg once, 63% [19 of 30]; 100 mg every other week for 12 weeks, 93% [28 of 30]; 200 mg weekly for 4 weeks, 90% [27 of 30]; 200 mg every other week for 12 weeks, 93% [28 of 30]; 200 mg weekly for 12 weeks, 90% [27 of 30]; placebo, 3% [1 of 30]; P < .001). Treatment with ABT-874 was well tolerated. The most common adverse event was injection-site reaction, and the most common infectious adverse events were nasopharyngitis and upper respiratory tract infection. There were no serious infectious adverse events.

Conclusions  ABT-874, an interleukin 12/23 monoclonal antibody, was highly effective and well tolerated in the treatment of psoriasis. Longer-term studies are required to confirm these findings.

Trial Registration  clinicaltrials.gov Identifier: NCT00292396

Author Affiliations: Clinical Unit for Research Trials in Skin (CURTIS), Massachusetts General and Brigham and Women's Hospitals, Harvard Medical School, Boston, Massachusetts (Dr Kimball); Division of Dermatology, Evanston Northwestern Healthcare, Evanston, Illinois (Dr Gordon); Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada (Dr Langley); Division of Dermatology, Department of Internal Medicine, Baylor Research Institute, Dallas, Texas (Dr Menter); Immunoscience, New Products, New Discovery, Abbott Laboratories, Parsippany, New Jersey (Dr Chartash); and Immunology Development, Abbott Laboratories, Abbott Park, Illinois (Dr Valdes).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events: A Meta-analysis of Randomized Controlled Trials
Ryan et al.
JAMA 2011;306:864-871.
ABSTRACT | FULL TEXT  

Advances in the treatment of moderate-to-severe plaque psoriasis
Herrier
Am J Health Syst Pharm 2011;68:795-806.
ABSTRACT | FULL TEXT  

IL-23-Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17A
Rizzo et al.
J. Immunol. 2011;186:1495-1502.
ABSTRACT | FULL TEXT  

Review of the safety and efficacy of ustekinumab
Scherl et al.
Therapeutic Advances in Gastroenterology 2010;3:321-328.
ABSTRACT